Scleroderma screening: Difference between revisions
m Template |
No edit summary |
||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Scleroderma}} | {{Scleroderma}} | ||
{{CMG}}; {{AE}} {{MKA}} | |||
==Overview== | |||
There is insufficient evidence to recommend routine screening for [disease/malignancy]. | |||
OR | |||
According to the [guideline name], screening for [disease name] is not recommended. | |||
OR | |||
According to the [guideline name], screening for [disease name] by [test 1] is recommended every [duration] among patients with [condition 1], [condition 2], and [condition 3]. | |||
==Screening== | ==Screening== | ||
There is insufficient evidence to recommend routine screening for [disease/malignancy]. | |||
OR | |||
According to the [guideline name], screening for [disease name] is not recommended. | |||
OR | |||
*According to the ACCF/AHA expert consensus document, screening for pulmonary arterial hypertension (PAH) by transthoracic echocardiogram (TTE) and pulmonary function tests (PFTs) is recommended every year among patients with scleroderma.<ref name="pmid19389575">{{cite journal |vauthors=McLaughlin VV, Archer SL, Badesch DB, Barst RJ, Farber HW, Lindner JR, Mathier MA, McGoon MD, Park MH, Rosenson RS, Rubin LJ, Tapson VF, Varga J |title=ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association |journal=J. Am. Coll. Cardiol. |volume=53 |issue=17 |pages=1573–619 |date=April 2009 |pmid=19389575 |doi=10.1016/j.jacc.2009.01.004 |url=}}</ref> | |||
According to the [guideline name], screening for [disease name] by [test 1] is recommended every [duration] among patients with: | |||
*[Condition 1] | |||
*[Condition 2] | |||
*[Condition 3] | |||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
{{WH}} | |||
{{WS}} | {{WS}} | ||
[[Category: (name of the system)]] | |||
Revision as of 20:10, 28 March 2018
|
Scleroderma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Scleroderma screening On the Web |
|
American Roentgen Ray Society Images of Scleroderma screening |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: M. Khurram Afzal, MD [2]
Overview
There is insufficient evidence to recommend routine screening for [disease/malignancy].
OR
According to the [guideline name], screening for [disease name] is not recommended.
OR
According to the [guideline name], screening for [disease name] by [test 1] is recommended every [duration] among patients with [condition 1], [condition 2], and [condition 3].
Screening
There is insufficient evidence to recommend routine screening for [disease/malignancy].
OR
According to the [guideline name], screening for [disease name] is not recommended.
OR
- According to the ACCF/AHA expert consensus document, screening for pulmonary arterial hypertension (PAH) by transthoracic echocardiogram (TTE) and pulmonary function tests (PFTs) is recommended every year among patients with scleroderma.[1]
According to the [guideline name], screening for [disease name] by [test 1] is recommended every [duration] among patients with:
- [Condition 1]
- [Condition 2]
- [Condition 3]
References
- ↑ McLaughlin VV, Archer SL, Badesch DB, Barst RJ, Farber HW, Lindner JR, Mathier MA, McGoon MD, Park MH, Rosenson RS, Rubin LJ, Tapson VF, Varga J (April 2009). "ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association". J. Am. Coll. Cardiol. 53 (17): 1573–619. doi:10.1016/j.jacc.2009.01.004. PMID 19389575.